Protek in brief
Protek is a listed company in the Healthcare sector, based in Russia. It was founded in 1990. Its last known market value was $846 M (January 2020); there is no current figure. It employs about 12,000 people. Its shares trade under the symbol PRTK.ME (Russia).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Protek
Protek (Russian: Протек) is a Russian company that includes drug manufacturing, retail, and distribution. It is one of the largest pharmaceutical companies of Russia. It was founded in 1990 by Vadim Yakunin and Grigor Khachaturov. In 2022, the company's revenue in Russia amounted to 257 billion rubles.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Protek timeline
- 1990
- 🏁· approximateFounded
Events of Protek from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Protek share price · Russia (PRTK.ME)
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Jul 14, 2020 | 99.30 | 99.90 | 99.00 | 99.60 | +0.1% | 11,390 |
| Jul 13, 2020 | 99.60 | 99.70 | 99.20 | 99.50 | -0.1% | 9,520 |
| Jul 10, 2020 | 99.10 | 99.70 | 99.10 | 99.60 | +0.3% | 5,130 |
| Jul 9, 2020 | 99.20 | 99.70 | 99.00 | 99.30 | -0.1% | 20,900 |
| Jul 8, 2020 | 99.60 | 99.70 | 98.90 | 99.40 | +0.1% | 30,150 |
| Jul 7, 2020 | 118.70 | 118.70 | 77.20 | 99.30 | -0.3% | 22,960 |
| Jul 6, 2020 | 99.50 | 100.00 | 99.00 | 99.60 | +0.5% | 34,260 |
| Jul 3, 2020 | 99.20 | 99.60 | 99.10 | 99.10 | -0.4% | 3,930 |
| Jul 2, 2020 | 99.40 | 99.60 | 98.80 | 99.50 | -0.2% | 18,110 |
| Jun 30, 2020 | 99.50 | 99.80 | 98.90 | 99.70 | +0.1% | 22,950 |
| Jun 29, 2020 | 99.40 | 99.60 | 99.10 | 99.60 | +0.6% | 22,950 |
| Jun 26, 2020 | 99.10 | 99.70 | 98.70 | 99.00 | -0.6% | 30,520 |
| Jun 25, 2020 | 99.50 | 99.60 | 98.90 | 99.60 | +0.1% | 17,160 |
| Jun 23, 2020 | 99.10 | 99.60 | 98.80 | 99.50 | 0.0% | 18,810 |
| Jun 22, 2020 | 99.00 | 99.60 | 98.80 | 99.50 | -0.1% | 26,100 |
| Jun 19, 2020 | 99.30 | 99.60 | 98.90 | 99.60 | 0.0% | 34,270 |
| Jun 18, 2020 | 99.00 | 99.60 | 98.80 | 99.60 | 0.0% | 110,910 |
| Jun 17, 2020 | 98.90 | 99.70 | 98.90 | 99.60 | +0.6% | 62,450 |
| Jun 16, 2020 | 99.00 | 99.60 | 98.80 | 99.00 | -0.2% | 15,130 |
| Jun 15, 2020 | 99.10 | 99.70 | 98.90 | 99.20 | +0.1% | 27,310 |
| Jun 11, 2020 | 98.90 | 99.60 | 98.80 | 99.10 | -0.5% | 41,880 |
| Jun 10, 2020 | 98.60 | 99.60 | 98.50 | 99.60 | 0.0% | 29,180 |
| Jun 9, 2020 | 99.30 | 99.70 | 98.20 | 99.60 | +1.0% | 57,340 |
| Jun 8, 2020 | 98.20 | 99.60 | 97.80 | 98.60 | -0.4% | 122,270 |
| Jun 5, 2020 | 98.70 | 99.60 | 98.00 | 99.00 | -0.3% | 69,110 |
| Jun 4, 2020 | 99.40 | 99.80 | 98.10 | 99.30 | +0.1% | 50,890 |
| Jun 3, 2020 | 99.30 | 101.50 | 99.10 | 99.20 | +0.2% | 23,430 |
| Jun 2, 2020 | 98.80 | 99.20 | 98.10 | 99.00 | +0.5% | 20,060 |
| Jun 1, 2020 | 99.00 | 99.00 | 98.00 | 98.50 | -0.1% | 7,700 |
| May 29, 2020 | 98.70 | 98.70 | 97.80 | 98.60 | — | 6,720 |
Prices in RUB from the Moscow Exchange; the last 30 trading days are listed, the chart shows up to ten years. For information only; not investment advice.
Protek share price statistics
Changes compare closing prices; volatility is the annualised standard deviation of daily returns. Prices are as published by the exchange, not adjusted for splits, bonus issues or dividends. For information only; not investment advice.
Market cap history
Not enough history yet.
Brands of Protek (1)#
Pharmacy chain · since 2001
Source: Wikidata. Brands whose Wikidata item names Protek (or a subsidiary of it) as owner, maker or parent organization; each brand's page links to its item
Protek scorecard#
Passes 2 of the 2 checks that could be worked out. Fiscal year 2017.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 2
- ✓Profitable in the newest year$101 MNet income $101 M in fiscal 2017.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✓Return on equity above 15%17.3%17.3% in fiscal 2017.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (wikidata), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Protek🇷🇺 | $846 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- UnitedHealth Group Incorporated$367.7 B
- Merck & Co., Inc.$359.8 B
Sources and freshness
- Market cap:
- Jan 1, 2020 (last known)
- Employees:
- 2012
- Profile updated:
- Nov 4, 2026
Figures from Wikidata, value.today research, Wikipedia.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Protek? Verify and update this profile — free
Show Protek's ranking on your website Get the badge
The badge updates itself as the ranking changes.